AD
ADMA.US ADMA Biologics Inc
- Market cap
- USD 2.94B
- P/E
- 17.2x
- P/B
- 6.67x
- ROE
- 40.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ADMA.US undervalued?
Graham numberADMA.US trades 125.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ADMA Biologics Inc fundamental analysis
No fundamental analysis for ADMA Biologics Inc yet.
ADMA Biologics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVI…
Full company profileADMA Biologics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ADMA Biologics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 10.7M | 22.8M | 17.0M | 29.3M | 42.2M | 80.9M | 154M | 258M | 426M | 510M | 507M |
| Gross Profit | 4.30M | -6.40M | -25.2M | -10.2M | -19.1M | 1.17M | 35.3M | 88.9M | 220M | 293M | 356M |
| Operating Income | -17.3M | -39.3M | -60.3M | -41.4M | -64.9M | -58.4M | -39.4M | 21.6M | 139M | 191M | 227M |
| EBITDA | -16.8M | -37.8M | -56.8M | -36.0M | -59.8M | -53.1M | -39.5M | 5.12M | 148M | 198M | 250M |
| Net Income | -19.5M | -43.8M | -65.7M | -48.3M | -75.7M | -71.6M | -65.9M | -28.2M | 198M | 147M | 177M |
| EPS | -1.61 | -1.91 | -1.45 | -0.89 | -0.88 | -0.51 | -0.33 | -0.13 | 0.81 | 0.60 | 0.79 |
| Balance Sheet | |||||||||||
| Total Assets | 23.7M | 108M | 88.9M | 127M | 208M | 276M | 348M | 329M | 489M | 624M | 732M |
| Total Liabilities | 28.1M | 67.7M | 69.1M | 101M | 119M | 135M | 196M | 194M | 140M | 147M | 294M |
| Shareholders' Equity | -4.46M | 40.3M | 19.8M | 26.2M | 88.2M | 141M | 152M | 135M | 349M | 477M | 439M |
| Cash & Short-term Investments | 15.3M | 43.1M | 22.8M | 26.8M | 55.9M | 51.1M | 86.5M | 51.4M | 103M | 87.6M | 125M |
| Total Debt | 20.3M | 43.0M | 44.2M | 84.7M | 97.7M | 103M | 154M | 141M | 82.1M | 79.9M | 203M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.3M | -37.3M | -62.7M | -76.2M | -102M | -112M | -59.5M | 8.80M | 119M | 50.4M | 140M |
| Capital Expenditure | 73.4K | 2.68M | 2.10M | 3.81M | 12.7M | 13.5M | 13.9M | 4.98M | 8.58M | 22.6M | 9.07M |
| Free Cash Flow | -18.3M | -39.9M | -64.8M | -80.0M | -115M | -126M | -73.4M | 3.82M | 110M | 27.8M | 131M |
| Ratios | |||||||||||
| ROE | - | -108.5% | -332.5% | -184.3% | -85.8% | -50.8% | -43.4% | -20.9% | 56.6% | 30.8% | 40.5% |
| ROA | -82.4% | -40.5% | -74.0% | -38.0% | -36.5% | -25.9% | -18.9% | -8.6% | 40.5% | 23.5% | 24.2% |
| Net Profit Margin | -183.1% | -192.3% | -387.1% | -164.5% | -179.4% | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% | 35.0% |
| Debt to Equity | - | 1.07x | 2.24x | 3.23x | 1.11x | 0.73x | 1.02x | 1.05x | 0.24x | 0.17x | 0.46x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ADMA Biologics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 2.90M | 0.01 | - |
| 2021 | USD 61.6K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ADMA Biologics Inc
- Insiders 1.97%
- Institutions 92.01%
- Public & others 6.02%
- Shares outstanding 222M
- Free float 218M
Top funds holding ADMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 13.5M | 6.07% | -0.11% | Oct 2026 |
| First Trust NYSE Arca Biotech ETF | 9.45M | 4.26% | 0.00% | Oct 2026 |
| American Funds SMALLCAP World A | 8.52M | 3.84% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6.52M | 2.94% | -7.42% | Sep 2026 |
| iShares Russell 2000 ETF | 5.84M | 2.63% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 4.87M | 2.19% | +2.69% | Oct 2026 |
| Fidelity Small Cap Index | 2.53M | 1.14% | +0.16% | Aug 2026 |
| Vanguard Small Cap Index | 2.40M | 1.08% | -5.37% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 2.17M | 0.98% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 2.05M | 0.93% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 2.02M | 0.91% | -0.32% | Oct 2026 |
| iShares Biotechnology ETF | 1.67M | 0.75% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 1.34M | 0.60% | +1.11% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.33M | 0.60% | -7.76% | Sep 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 1.27M | 0.57% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 1.19M | 0.54% | +0.24% | Oct 2026 |
| DFA U.S. Small Cap I | 1.04M | 0.47% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 1.04M | 0.47% | -8.68% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 1.03M | 0.47% | -33.98% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 952K | 0.43% | 0.00% | Sep 2026 |
Top institutions holding ADMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 38.4M | 17.29% | +4.14% | Jun 2026 |
| State Street Corp | 17.1M | 7.72% | +21.53% | Jun 2026 |
| Vanguard Capital Management, LLC | 10.1M | 4.55% | -1.97% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 10.1M | 4.55% | +13.75% | Jun 2026 |
| Rubric Capital Management LP | 9.34M | 4.21% | +416.16% | Jun 2026 |
| Capital Research Global Investors | 8.76M | 3.95% | -21.76% | Jun 2026 |
| First Trust Advisors L.P. | 7.80M | 3.52% | +2,064.90% | Jun 2026 |
| Geode Capital Management, LLC | 6.06M | 2.73% | +4.05% | Jun 2026 |
| Caligan Partners LP | 5.73M | 2.58% | +20.36% | Jun 2026 |
| D. E. Shaw & Co LP | 5.27M | 2.38% | +840.50% | Jun 2026 |
| Nantahala Capital Management, LLC | 4.72M | 2.13% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.54M | 1.60% | -1.71% | Sep 2026 |
| The Goldman Sachs Group Inc | 3.51M | 1.58% | +25.33% | Jun 2026 |
| B Group, Inc | 3.26M | 1.47% | +1.71% | Jun 2026 |
| Nuveen, LLC | 3.26M | 1.47% | -46.54% | Jun 2026 |
| Duquesne Family Office LLC | 2.78M | 1.25% | +80.13% | Jun 2026 |
| Northern Trust Corp | 2.42M | 1.09% | +6.09% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.27M | 1.02% | -6.94% | Jun 2026 |
| Ranger Investment Management LP | 2.12M | 0.95% | -7.37% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.09M | 0.94% | -0.15% | Jun 2026 |
ADMA Biologics Inc company profile
- Company name
- ADMA Biologics Inc
- Ticker
- ADMA.US
- Exchange
- USA Stocks
- Listed since
- Oct 17, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 640
- Fiscal year end
- December
- Address
- 465 State Route 17, Ramsey, NJ, United States, 07446
- Phone
- 201 478 5552
- Website
- admabiologics.com
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Biologics Inc management
8- Mr. Adam S. GrossmanCo-Founder, President, CEO & Director · born 1977
- Dr. Jerrold B. Grossman D.P.S., Ph.D.Co-Founder & Vice Chairman of the Board · born 1948
- Mr. P. Terence KohlerCFO & Treasurer
- Ms. Kaitlin M. KestenbergCOO & Senior VP of Compliance · born 1987
- Mr. Michael GoldsteinGeneral Counsel
- Mr. John HaflExecutive Director of Sales
- Mr. R. Duane Clark IISenior Vice President of Commercial Operations · born 1963
- Mr. Skyler BloomSenior Director of Business Development & Corporate Strategy